caa a22 4500 397593678 CHVBK 20180308164946.0 cr unu---uuuuu 161202e199606 xx s 000 0 eng 10.1093/jac/37.suppl_C.151 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_C.151 Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin [Elektronische Daten] [C. Carbon, J. M. Hotton, L. F. Pépin, C. Wohlhuter, E. Souêtre, M. Hardens, H. Lozet, M. Riviera] The economic impacts in terms of cost and effectiveness (speed of resolution of symptoms) of 3- and 5-day courses of azithromycin and a 10-day course of roxithromycin were compared in a randomized, open study in patients with symptoms suggestive of β-haemolytic streptococcal pharyngitis. Direct medical costs and absence from work were recorded and symptom scores and compliance were used to assess the effectiveness of therapies. Although no differences between treatment groups in terms of overall clinical response rates were detected 2 and 4 weeks after the start of treatment, more rapid resolution of symptoms was achieved with 3- and 5-day courses of azithromycin than with a 10-day course of roxithromycin. There was also a significant reduction in the time absent from work in the azithromycin treatment groups. The total costs of care over the 4-week evaluation period were lower for the 3- and 5-day azithromycin courses (US$193.60 and US$195.30 respectively) than for roxithromycin (US$202.10). The major cost components were absence from work (58.6%), visits to the physician (15.3%) and utilization of antibiotics (14.9%). Compliance was significantly better (P < 0.01) in patients prescribed azithromycin for 3 and 5 days (58.0% and 42.9% respectively) than in those who received roxithromycin (20.3%) and a significantly longer symptom-free period (P < 0.01) was reported in azithromycin- compared with roxithromycin-treated patients. These findings support the hypothesis that a 3- or 5-day course of azithromycin is as effective as a 10 day course of roxithromycin in the treatment of patients with pharyngitis and is associated with lower costs. Furthermore, azithromycin is associated with faster resolution of symptoms and improved patient compliance. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Carbon C. Service des Maladies Infectieuses, Hôpital Bichat Paris, France aut Hotton J. M. Pfizer France Orsay, France aut Pépin L. F. Pfizer France Orsay, France aut Wohlhuter C. Pfizer France Orsay, France aut Souêtre E. Benefit Research Group Gennevilliers, France aut Hardens M. Benefit Research Group, Leiden The Netherlands aut Lozet H. Benefit Research Group Gennevilliers, France aut Riviera M. Benefit Research Group Gennevilliers, France aut Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 151-161 0305-7453 37<151 1996 37 jac https://doi.org/10.1093/jac/37.suppl_C.151 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_C.151 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Carbon C. Service des Maladies Infectieuses, Hôpital Bichat Paris, France aut NATIONALLICENCE 700 1- Hotton J. M. Pfizer France Orsay, France aut NATIONALLICENCE 700 1- Pépin L. F. Pfizer France Orsay, France aut NATIONALLICENCE 700 1- Wohlhuter C. Pfizer France Orsay, France aut NATIONALLICENCE 700 1- Souêtre E. Benefit Research Group Gennevilliers, France aut NATIONALLICENCE 700 1- Hardens M. Benefit Research Group, Leiden The Netherlands aut NATIONALLICENCE 700 1- Lozet H. Benefit Research Group Gennevilliers, France aut NATIONALLICENCE 700 1- Riviera M. Benefit Research Group Gennevilliers, France aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 151-161 0305-7453 37<151 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford